↓
 

Tag Archives: pembrolizumab

Drs. Jack West and Charu Aggarwal: New Data on Liquid Biopsies, Tumor Mutational Burden, and Choosing Optimal Systemic Therapy Today

Dr. Charu Aggarwal from University of Pennsylvania Abramson Cancer Center joins Dr. Jack West to discuss new data on plasma-based testing for tumor mutational burden (TMB) & the current state of liquid biopsies, TMB, & immunotherapy-based options today. (36:57)

Dr. Hossein Borghaei (Pt 2): Reflecting on Progress & Future Directions in Immunotherapy

Drs. Hossein Borghaei and host Jack West discuss long term outcomes in lung cancer with immunotherapy, potential utility of IO combinations, and when we can consider patients doing well on immunotherapy as cured if doing well beyond 5 years. (26:22)

Dr. Jack West on New Data Combining Radiation with Immunotherapy in Advanced NSCLC: A Brief Critical Review

Dr. Jack West provides a brief summary of key findings & limitations of two new papers just out in JAMA Oncology (Theelen et al & Bauml et al.) that evaluate the potential benefit of preceding immunotherapy with radiation in patients with advanced NSCLC. (18:00)

Dr. Jack West: Why the Broader FDA Approval of First Pembrolizumab Monotherapy based on KEYNOTE-042 is an Invitation to Inferior Care in Advanced NSCLC

Dr. Jack West reviews why the new FDA approval of first line pembrolizumab monotherapy for the 1-49% PD-L1 subgroup won on a technicality and now offers a clearly inferior choice compared to far better existing standards for patients with low tumor PD-L1. (20:08)

Weighing the clinical significance of new clinical trial results with immunotherapy in stage III and IV NSCLC

Drs. Jack West & Corey Langer debate the criteria for adopting early clinical data as practice-changing as immunotherapy trials in locally advanced & metastatic NSCLC are reported. (19:05)

Dr. David Spigel, Part 2: Identifying the Optimal Duration for Immunotherapy in Responding Patients with Advanced Lung Cancer

Dr. Jack West interviews Dr. David Spigel of Sarah Cannon Research Institute on the challenges of conducting clinical trials and delivering increasingly complex patient care, along with the possible future role of artificial intelligence and telemedicine. (20:36)

Top 5 Most Influential Trial Findings in Lung Cancer Management in 2018 (BMIC-073)

Dr. Jack West summarizes his list of the top 5 most influential trials in lung cancer that reported results in 2018, including why they matter. (13:27)

Download MP3 Audio Version

Pembrolizumab for Patients with Advanced NSCLC and a Performance Status (PS) of 2: Results of the PePS2 Trial (BMIC-067)

Dr. Jack West summarizes new information presented at ESMO 2018 on the PePS2 trial of pembrolizumab (Keytruda) in patients with advanced NSCLC performance status (PS) of 2, which demonstrated favorable efficacy and no concerning challenges with toxicity in this population. (4:12)

Download MP3 Audio Version

Long-Term Management of Patients Doing Well on Immunotherapy for Advanced NSCLC: Insights from KEYNOTE-010 (BMIC-066)

Dr. Jack West reviews longitudinal outcomes for patients on the KEYNOTE-010 trial of pembrolizumab (Keytruda) vs. docetaxel as 2nd line therapy for advanced NSCLC, with helpful new info on those completing 2 years of pembro & implications for practice. (8:03)

Download MP3 Audio Version

Immunotherapy with Pembrolizumab in Metastatic Prostate Cancer: Highlights in GU Oncology from ASCO 2018 (BMIC-055)

Dr. Daniel Goldstein summarizes key data in genitourinary oncology from ASCO 2018, including new results on pembrolizumab (Keytruda) for metastatic prostate cancer, asking whether it could find a place as treatment for a subset of these patients. (2:17)

Download MP3 Audio Version

↑